The drug showed promise, but the client lacked the insight to confidently design a trial that would differentiate their asset and drive approval. They needed to understand disease prevalence, key clinical and commercial benchmarks, and who was shaping opinion in the space. Time was short and decisions couldn’t wait.
We began by building a comprehensive clinical landscape, synthesizing data from literature reviews, publication databases, competitive trial registries, pricing intelligence, and real-world signals from digital sources.
Our data science team created custom dashboards to visualize incidence, prevalence, and risk factors, layered by geography and demographic. We mapped KOLs based on publication activity and digital influence, identified gaps in the treatment landscape, and conducted social listening to monitor competitor sentiment and emerging concerns around adverse events.
Each element was delivered through a collaborative insight board tailored to their strategic questions. This allowed for rapid exploration and alignment across the client’s R&D, medical, and commercial teams.
The client received a bespoke, integrated intelligence board designed to support both immediate trial design and long-term positioning. They could explore the epidemiology and market context in detail, understand how their asset fit within the treatment paradigm, and identify strategic opportunities to stand out.
We helped them understand not just what the data said, but why it mattered and how to act on it.
The insights empowered the client to refine their Phase 3 trial strategy with confidence. They could choose trial endpoints aligned to unmet need, engage the right KOLs, and begin developing a more credible narrative for regulators and investors. What started as a data gap became a source of strategic strength.
We continued to support the client by transforming the initial board into a live, always-available platform. It now serves as a cross-functional reference tool for their clinical, medical, and commercial teams, helping them stay alert to competitor shifts, publication trends, and evolving stakeholder sentiment as the asset progresses.
